Rivastigmine as a Symptomatic Treatment for Apathy in Parkinson’s Dementia Complex: New Aspects for This Riddle
Over 90% of PDD patients show at least one neuropsychiatric symptom (NPS); in the 60–70% two or more NPS are present. Their incidence is important in terms of prognosis and severity of pathology. However, among all NPS, apathy is often the most disturbing, associated with greater caregiver’s burden....
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | Parkinson's Disease |
| Online Access: | http://dx.doi.org/10.1155/2017/6219851 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850173332835532800 |
|---|---|
| author | Rita Moretti Paola Caruso Matteo Dal Ben |
| author_facet | Rita Moretti Paola Caruso Matteo Dal Ben |
| author_sort | Rita Moretti |
| collection | DOAJ |
| description | Over 90% of PDD patients show at least one neuropsychiatric symptom (NPS); in the 60–70% two or more NPS are present. Their incidence is important in terms of prognosis and severity of pathology. However, among all NPS, apathy is often the most disturbing, associated with greater caregiver’s burden. Similar to other NPS, apathy may be due to a dysfunction of the nigrostriatal pathway, even though, not all the PD patients become apathetic, indicating that apathy should not entirely be considered a dopamine-dependent syndrome, and in fact it might also be related to acetylcholine defects. Apathy has been treated in many ways, without sure benefits; among these, Rivastigmine may present benefic properties. We present a series of 48 patients, suffering from PDD, treated with Rivastigmine, and followed-up for one year; they have been devotedly studied for apathy, even though all the other NPS disorders have been registered. Rivastigmine did not have a prolonged benefic effect on apathy, in our work, on the contrary of what had been observed in the literature, probably due to the longer follow-up of our patients. |
| format | Article |
| id | doaj-art-cd465ccf2f0d4bdea8c51e01fd20fdfc |
| institution | OA Journals |
| issn | 2090-8083 2042-0080 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Parkinson's Disease |
| spelling | doaj-art-cd465ccf2f0d4bdea8c51e01fd20fdfc2025-08-20T02:19:52ZengWileyParkinson's Disease2090-80832042-00802017-01-01201710.1155/2017/62198516219851Rivastigmine as a Symptomatic Treatment for Apathy in Parkinson’s Dementia Complex: New Aspects for This RiddleRita Moretti0Paola Caruso1Matteo Dal Ben2Clinica Neurologica, Dipartimento Universitario Clinico di Scienze Mediche, Chirurgiche e della Salute, Università degli Studi di Trieste, Trieste, ItalyClinica Neurologica, Dipartimento Universitario Clinico di Scienze Mediche, Chirurgiche e della Salute, Università degli Studi di Trieste, Trieste, ItalyFIF Science Park, University of Trieste, Trieste, ItalyOver 90% of PDD patients show at least one neuropsychiatric symptom (NPS); in the 60–70% two or more NPS are present. Their incidence is important in terms of prognosis and severity of pathology. However, among all NPS, apathy is often the most disturbing, associated with greater caregiver’s burden. Similar to other NPS, apathy may be due to a dysfunction of the nigrostriatal pathway, even though, not all the PD patients become apathetic, indicating that apathy should not entirely be considered a dopamine-dependent syndrome, and in fact it might also be related to acetylcholine defects. Apathy has been treated in many ways, without sure benefits; among these, Rivastigmine may present benefic properties. We present a series of 48 patients, suffering from PDD, treated with Rivastigmine, and followed-up for one year; they have been devotedly studied for apathy, even though all the other NPS disorders have been registered. Rivastigmine did not have a prolonged benefic effect on apathy, in our work, on the contrary of what had been observed in the literature, probably due to the longer follow-up of our patients.http://dx.doi.org/10.1155/2017/6219851 |
| spellingShingle | Rita Moretti Paola Caruso Matteo Dal Ben Rivastigmine as a Symptomatic Treatment for Apathy in Parkinson’s Dementia Complex: New Aspects for This Riddle Parkinson's Disease |
| title | Rivastigmine as a Symptomatic Treatment for Apathy in Parkinson’s Dementia Complex: New Aspects for This Riddle |
| title_full | Rivastigmine as a Symptomatic Treatment for Apathy in Parkinson’s Dementia Complex: New Aspects for This Riddle |
| title_fullStr | Rivastigmine as a Symptomatic Treatment for Apathy in Parkinson’s Dementia Complex: New Aspects for This Riddle |
| title_full_unstemmed | Rivastigmine as a Symptomatic Treatment for Apathy in Parkinson’s Dementia Complex: New Aspects for This Riddle |
| title_short | Rivastigmine as a Symptomatic Treatment for Apathy in Parkinson’s Dementia Complex: New Aspects for This Riddle |
| title_sort | rivastigmine as a symptomatic treatment for apathy in parkinson s dementia complex new aspects for this riddle |
| url | http://dx.doi.org/10.1155/2017/6219851 |
| work_keys_str_mv | AT ritamoretti rivastigmineasasymptomatictreatmentforapathyinparkinsonsdementiacomplexnewaspectsforthisriddle AT paolacaruso rivastigmineasasymptomatictreatmentforapathyinparkinsonsdementiacomplexnewaspectsforthisriddle AT matteodalben rivastigmineasasymptomatictreatmentforapathyinparkinsonsdementiacomplexnewaspectsforthisriddle |